Kura Oncology Inc., a clinical-stage biopharmaceutical company, announced on August 4, 2025, that its Compensation Committee has granted inducement awards consisting of nonstatutory stock options to thirty-five new employees. The awards, approved under the Company's 2023 Inducement Option Plan, allow these employees to purchase a total of 646,700 shares of common stock at an exercise price of $6.02 per share, the closing price on August 1, 2025. The stock options will vest over a period of four years, with 25% vesting after one year and the remaining shares vesting monthly over the next 36 months, contingent on the employees' continued service with the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.